厄洛替尼致消化系统严重不良反应文献分析

Literature analysis on severe adverse drug reactions of digestive system by Erlotinib

目的探究厄洛替尼所致消化系统严重不良反应(ADRs)的发生情况和临床特点,为临床合理用药提供参考。方法检索从建库至2020年1月中国学术期刊全文数据库(CNKI)、维普中文科技期刊数据库(VIP)、PubMed、Medline、Web of Science数据库收载的厄洛替尼所致消化系统严重ADRs文献,进行统计分析。结果厄洛替尼导致消化系统严重ADRs的个案报道共25例次;其年龄分布以51~80岁年龄段较多(20例,80%);多发生用药后8周内(19例,76%),以胃肠道穿孔(24%)、药物性肝损伤(52%)多见,且出现了新的严重ADRs如反射性回忆性胃炎。结论临床医师和药师需加强对厄洛替尼致消化系统严重ADRs的认识和监测,谨慎评估再次给药的治疗风险,保证临床用安全、有效。

Objective To explore the occurrence and clinical characteristics of serious adverse drug reactions(ADRs)of the digestive system caused by Erlotinib,and to provide references for clinical rational use of drugs.Methods The literature on ADRs of the digestive system caused by Erlotinib contained in the Chinese national knowledge infrastructure(CNKI),VIP,PubMed,Medline,and Web of Science from the establishment of the database to January 2020 were searched,while they were performed statistical analysis.Results There were 25 cases of severe ADRs in the digestive system caused by Erlotinib;the age distribution was 51 to 80 years old(20 cases,80%);most of them occur within 8 weeks after medication(19 cases,76%);it was more common with gastrointestinal perforation(24%),drug-induced liver injury(52%),and new serious ADRs such as reflex reminiscence gastritis.Conclusion Clinicians and pharmacists need to strengthen their understanding and monitoring of severe ADRs in the digestive system caused by Erlotinib,and carefully evaluate the treatment risks of re-dose to ensure safe and effective clinical use.